GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HPGC Renmintongtai Pharmaceutical Corp (SHSE:600829) » Definitions » Interest Expense

HPGC Renmintongtai Pharmaceutical (SHSE:600829) Interest Expense : ¥-26 Mil (TTM As of Mar. 2024)


View and export this data going back to 1994. Start your Free Trial

What is HPGC Renmintongtai Pharmaceutical Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. HPGC Renmintongtai Pharmaceutical's interest expense for the three months ended in Mar. 2024 was ¥ -7 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-26 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. HPGC Renmintongtai Pharmaceutical's Operating Income for the three months ended in Mar. 2024 was ¥ 111 Mil. HPGC Renmintongtai Pharmaceutical's Interest Expense for the three months ended in Mar. 2024 was ¥ -7 Mil. HPGC Renmintongtai Pharmaceutical's Interest Coverage for the quarter that ended in Mar. 2024 was 16.94. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

HPGC Renmintongtai Pharmaceutical Interest Expense Historical Data

The historical data trend for HPGC Renmintongtai Pharmaceutical's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HPGC Renmintongtai Pharmaceutical Interest Expense Chart

HPGC Renmintongtai Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -25.28 -30.75 -50.32 -44.42 -27.23

HPGC Renmintongtai Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.01 -6.61 -5.36 -7.26 -6.53

HPGC Renmintongtai Pharmaceutical Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HPGC Renmintongtai Pharmaceutical  (SHSE:600829) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

HPGC Renmintongtai Pharmaceutical's Interest Expense for the three months ended in Mar. 2024 was ¥-7 Mil. Its Operating Income for the three months ended in Mar. 2024 was ¥111 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was ¥17 Mil.

HPGC Renmintongtai Pharmaceutical's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Interest Coverage=-1* Operating Income (Q: Mar. 2024 )/Interest Expense (Q: Mar. 2024 )
=-1*110.71/-6.534
=16.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

HPGC Renmintongtai Pharmaceutical (SHSE:600829) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HPGC Renmintongtai Pharmaceutical Corp (SHSE:600829) » Definitions » Interest Expense
Comparable Companies
SHSE:688176 SZSE:301277 SZSE:002644 SZSE:300485 SZSE:002923 SHSE:603676 SHSE:688247 SHSE:603168 SZSE:002940 SHSE:603520 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ VTRS SZSE:000538 NBIX
Traded in Other Exchanges
N/A
Address
No. 76 Hengshan Road, Nangang District, Heilongjiang Province, Harbin, CHN, 150076
Website
http://www.sanjing.com.cn
HPGC Renmintongtai Pharmaceutical Corp, formerly Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co Ltd is engaged in the production and sale of pharmaceuticals products in China.

HPGC Renmintongtai Pharmaceutical (SHSE:600829) Headlines

No Headlines